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Abstract: Numerous investigations of microbial surface-active compounds or biosurfactants over the 
past two decades have led to the discovery of many interesting physicochemical and biological 
properties including antimicrobial, anti-biofilm and therapeutic among many other pharmaceutical 
and medical applications. Microbial control and inhibition strategies involving the use of antibiotics 
are becoming continually challenged due to the emergence of resistant strains mostly embedded 
within biofilm formations that are difficult to eradicate. Different aspects of antimicrobial and 
anti-biofilm control are becoming issues of increasing importance in clinical, hygiene, therapeutic 
and other applications. Biosurfactants research has resulted in increasing interest into their ability to 
inhibit microbial activity and disperse microbial biofilms in addition to being mostly nontoxic and 
stable at extremes conditions. Some biosurfactants are now in use in clinical, food and environmental 
fields, whilst others remain under investigation and development. The dispersal properties of 
biosurfactants have been shown to rival that of conventional inhibitory agents against bacterial, 
fungal and yeast biofilms as well as viral membrane structures. This presents them as potential 
candidates for future uses in new generations of antimicrobial agents or as adjuvants to other 
antibiotics and use as preservatives for microbial suppression and eradication strategies. 
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1. Introduction  
Biosurfactants comprise a wide range of surface-active structurally different organic compounds 
produced by numerous prokaryotic and eukaryotic microorganisms. These compounds are generally 
extracellularly excreted or localized on microbial cell surfaces and are made of amphiphilic 
molecules in which the hydrophobic moiety may include an acid, mono-, di- or polysaccharides, 
peptide cations, or anions, while the hydrophobic moiety may be composed of saturated or 
unsaturated fatty acid or hydrocarbon chains [1]. Biosurfactants are generally grouped according to 
their chemical structure, molecular weight, and mode of action. The best studied biosurfactants are 
glycolipids such as rhamnolipids, trehalolipids, sophorolipids and mannosylerythritol lipids and 
lipopeptides such as surfactin and fengycin. 
These compounds orientation and behaviour on surfaces and interphases confers to these 
compounds a range of properties, such as the ability to decrease surface and interfacial tension of 
liquids and the formation of microemulsions and micelles between different phases [2,3]. 
Biosurfactants tend to aggregate in heterogeneous systems and at interfaces or boundaries and to 
form molecular interfacial films that alters the original properties of these surfaces.  
In the past twenty years, a large volume of research activity has been dedicated to biosurfactants 
as potential replacement for synthetic surfactants in many industrial and environmental applications 
such as detergent, textile, paint, cosmetic, bioremediation, enhanced oil recovery, food, agrochemical 
fields and several commercial products have already been manufactured [4].  
More recently, numerous investigations have led to the discovery of several interesting 
biological and chemical properties of biosurfactants and several pharmaceutical and medical 
applications have been envisaged [5,6]. In particular, the ability to disturb membranes integrity 
destabilizing them and permeability leading to metabolite leakage and cell lysis [7–10], as well as 
their propensity to partition at the interfaces, modifying surface properties and thus affecting 
microorganisms adhesion, which are important functions for antimicrobial and anti-biofilm 
applications [11]. Additionally, some experimental results have suggested that they are non-toxic or 
less toxic when compared to synthetic surfactants [12,13], a valuable characteristic for biomedical 
applications. 
In this review, we focus on recent advances on biosurfactants as antimicrobial and anti-adhesive 
compounds, with a brief overview on the latest outcome on innovative therapeutic and 
biotechnological applications. 
2. Biosurfactants as Biological Control Agents 
The urgent need for new antimicrobial compounds nowadays remains of major concern due to 
the newly emerging pathogens and other conventional ones the majority of which have become 
almost insensitive to existing antibiotics [14]. Microbial metabolites are also known as a major 
source of compounds categorized with potent biological activities and, among these, some 
biosurfactants have been described as adjuvants or potential alternatives to antimicrobial agents and 
synthetic medicines [11]. Moreover, in addition to their ability to modulate the interaction of cells 
with surfaces, biosurfactants are able to interfere with microbial adhesion and biofilm formation, an 
important and frequently hazardous manifestations on medical devices, especially as such biofilms 
contain bacterial strains that often become highly resistant to adverse environmental challenges and 
antibiotics [15,16]. It would be useful therefore to increase the efficacy of known biocides and 
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antibiotics with alternative strategies aimed at reducing the biofilm populations and decreasing 
bacterial adhesion to medical devices surfaces. 
2.1. Mechanisms of action 
Establishing the functional mechanisms of actions for biosurfactants is of immense importance 
to assist the discovery of interesting applications. Among biosurfactants, lipopeptides and glycolipids 
have the most potent antimicrobial activity and represent an important source for the identification of 
new antibiotics. 
2.1.1. Lipopeptide type compounds 
The antimicrobial activities of lipopeptides, such as surfactin [17] and fengycin [18], are due to 
their ability to self-associate and form micellular aggregates or pore-bearing channels inside the lipid 
membrane. Due to these properties, lipopeptides usually cause membrane disruption, increased 
membrane permeability, metabolite leakages and cell lysis. Furthermore, membrane structure 
changes and disruption of protein conformations alter vital membrane functions including energy 
generation and transport [19,20]. Studies carried out on daptomycin showed that the lipopeptide 
oligomer binding which can be Ca2+ dependent often leads to the formation of pores within the 
membranes [21]. These pores may lead to membrane disruption and cell death as a result of 
transmembrane ion influxes, including Na+ and K+ [22]. The bactericidal activity of lipopeptides 
increases with the presence of a lipid tail length of 10–12 carbons atoms whereas an enhanced 
antifungal activity is exhibited in lipopeptides with a lipid tail length of 14 or 16 carbon atoms [20]. 
In addition, due to the difficulty of the target cells to reorganize their membranes, the ability to 
develop resistant strains is significantly diminished [22].  
Surfactin, which is often described as a powerful biosurfactant has the capability to disturb the 
integrity and permeability of membranes destabilizing them. In fact, surfactin generates physical 
structural changes in the membrane or disrupts protein conformations, which can change some 
central membrane functions such as the generation of energy and transport [7–9,23]. One of the 
crucial steps for cellular membrane leakage and destabilization is the dimerization of surfactin into 
its bilayer [17]. Surfactin incorporation into membranes, in vitro, leads to the dehydration of the head 
groups of the phospholipid and bilayer instability due to the perturbation of lipid packing which 
ultimately leads to the alteration and distortion of the membrane barrier properties [17]. For antiviral 
activity, surfactin acts directly on the mainly lipidic viral envelope causing leakages or complete 
disintegration of the envelope exposing the capsid of the virus particles, which leads to loss 
infectivity. 
Mechanisms of action and activity of other lipopeptides have recently been reviewed by 
Cochrane and Vederas [24]. Polymyxins primarily exert their strong bactericidal effect against 
Gram-negative bacteria through the binding of the lipid A component of lipopolysaccharide (LPS) 
and disruption of the outer membrane, followed by the permeabilization and disruption of the inner 
membrane [25,26]. Octapeptins A and B display broad-spectrum activity against both Gram-positive 
and Gram-negative bacteria and have also antimicrobial activity against some filamentous fungi, 
protozoa and yeasts due to their ability to disrupt the cytoplasmic membrane. The iturin family 
compounds exerts fungicidal action through the interaction with sterol components in the fungal 
membrane, leading to an increase in K+ permeability [27]. It is generally believed that the first step in 
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the interaction between a surfactant and a bacterial cell consists of an ionic adsorption to the bacterial 
cell wall which is followed by damage to cell membrane leading to inactivation of metabolic 
processes and cell lysis. The role or preferential attachment of surfactants to the Gram-positive or 
negative cell wall may be a potential explanation to their selective activity on either types of cells but 
yet remains to be established.    
2.1.2. Glycolipidic type compounds 
Concerning glycolipidic compounds mode of action, Sotirova et al. [28] demonstrated that the 
exposure of Pseudomonas aeruginosa to rhamnolipids causes a multi-component response of the 
bacterial cells characterized by a reduction of total cellular LPS content, an increase in cell 
hydrophobicity and changes in membrane proteins and surface morphology. In the same way, 
antimicrobial activity of sophorolipids involves mechanisms that cause destabilization and alteration 
of the permeability of the cellular membrane [29]. Furthermore, Ortiz et al. [7] have recently 
reported on the interactions of bacterial biosurfactants trehalose lipids with phosphatidylserine and 
phosphatidylethanolamine membranes. Their results demonstrated that trehalose lipids, when 
incorporated into the bilayers, increased hydrocarbon chain conformational disorder and decreased 
the hydration of the interfacial region of the bilayer, leading to structural perturbations that might 
affect membranes functions. 
The ability to reduce microbial cells adhesion to surfaces, thus limiting biofilm formation, is 
another well-known property of biosurfactants. Both numbers and initial deposition rates of 
microorganisms adhering to surfaces are determined by complex interactions of hydrophobicity 
(interfacial free energies), the presence of specific receptor sites on the microbial cell surfaces, 
electrostatic interactions and types of biosurfactants produced. In particular, biofilm formation on 
solid surfaces is generally directly proportional to the hydrophobicity of the surface, as long as the 
suspended medium is a simple buffer [30]. Microbial adhesion on hydrophobic substrates (e.g. 
silicone rubber) was speculated to be related to the removal of interfacial water between 
microorganism and interacting surfaces, which facilitates closer approach and adhesion [31]. The 
authors also advocated that biosurfactants reduce hydrophobic interactions which decrease surface 
hydrophobicity that ultimately hinders microbial adhesion to surfaces and subsequently interferes 
with biofilms development. 
2.2. Antimicrobial activity of biosurfactants 
2.2.1. Biosurfactant activity against human pathogenic bacteria and fungi 
The most commonly reported class of biosurfactants with antimicrobial activity, are 
lipopeptides [24]. Antimicrobial lipopeptides include surfactin, iturin, fengycin, mycosubtilins and 
bacillomycins produced by Bacillus subtilis, [32], cyclic lipopeptides such as daptomycin, from 
Streptomyces roseosporus [33], polymyxin B, pumilacidin and lichenysin produced by Bacillus 
polymyxa, Bacillus pumilus and Bacillus licheniformis, respectively [34] and finally viscosin, from 
Pseudomonads [35]. Glycolipids, have also been reported to display antimicrobial activities, in 
particular, rhamnolipids from P. aeruginosa [36], sophorolipids from Candida bombicola [37,38], 
mannosylerythritol lipids (MEL-A and MEL-B) from Candida antarctica [39]. 
Ghribi et al. [40] reported a broad spectrum antimicrobial activity against bacteria and fungi and 
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effects against multidrug-resistant microbial strains for a biosurfactant produced by B. subtilis SPB1. 
The compound showed less activity against Gram-negative bacilli and higher activity against 
Gram-positive cocci with particularly significant effects against Enterococcus faecalis.  
Using strain Paenibacillus elgii B69, Ding et al. [41] isolated two lipopeptide antibiotics, 
pelgipeptins C and D which were active against pathogenic Candida fungal strains and a number of 
Gram-negative and Gram-positive bacteria. In particular, pelgipeptin D exhibited effective rapid 
bactericidal action against a methicillin resistant strain of Staphylococcus aureus and with an 
intraperitoneal LD50 acute toxicity test values slightly higher than polymyxin B a structurally related 
antimicrobial agent. Tabbene et al. [42] also reported three anti-Candida albicans compounds (a1, a2 
and a3) derived from B. subtilis B38 and resembling bacillomycin D-like lipopeptides. Compound a3 
had strongest fungicidal activity exceeding amphotericin B activity against a pathogenic strain of C. 
albicans sp. 311 isolated from fingernail.  
More recently, a lipopeptide produced by B. licheniformis M104 were investigated as 
antimicrobial agent against Gram-positive bacteria (B. subtilis, B. thuringiensis, B. cereus, S. aureus 
and Listeria monocytogenes), Gram-negative bacteria (P. aeruginosa, Escherichia coli, Salmonella 
typhimurium, Proteus vulgaris, Klebsiella pneumoniae) and C. albicans [43]. All the tested 
microorganisms, with the exception of L. monocytogenes and K. pneumoniae, were affected by the 
biosurfactant and S. aureus was the most susceptible. The antimicrobial effect of the lipopeptide was 
time and concentration-dependent. The maximum inhibitory activity was observed at a concentration 
of 48 μg ml−1 after 12h of treatment. The lipopeptide 6–2 produced by Bacillus amyloliquefaciens 
was also found to have interesting antifungal activity against C. albicans, Metschnikowia bicuspidate, 
Candida tropicalis, Yarrowia lipolytica and Saccharomyces cerevisiae [44]. Scanning electronic 
microscopy revealed the mode of action of lipopeptide 6–2 against C. albicans showing the presence 
of invaginations in the cell wall, disruption of the whole cells followed by the loss of integrity of the 
cell wall. They also reported that lipopeptide 6–2 biosurfactant damaged the plasma membranes of C. 
albicans protoplast leading to its lysis [44].  
Very recently, Sharma et al. [45] purified and characterized a novel lipopeptide from 
Streptomyces amritsarensis sp. The antimicrobial activity of the biosurfactant was evaluated on a 
broad spectrum of bacteria and fungi. The MIC values of purified lipopeptide against B. subtilis, 
Staphylococcus epidermidis, Mycobacterium smegmatis strains and a methicillin resistant S. aureus 
(MRSA) were reported to be 10, 15, 25 and 45 μg ml−1, respectively. No activity against any of the 
tested Gram-negative bacteria and against fungi was observed. The surface-active lipopeptide heat 
stability test established that exposure to 100 °C or 121 °C for 15min reduced the antimicrobial 
action by 13.7% and 18.2% respectively. It also showed both non-cytotoxic and non-mutagenic 
properties, which are important prerequisite for drug development.  
Liang et al. [46] analysed the antimicrobial effect of a biosurfactant obtained by cultivating the 
strain Paenibacillus macerans TKU029 in a medium with 2% (w/v) squid pen powder as 
carbon/nitrogen source. The purified TKU029 biosurfactant displayed significant inhibitory effect on 
E. coli and S. aureus at concentrations of 2 and 1.5 mg ml-1 respectively and showed good antifungal 
activity against Fusarium oxysporum and Aspergillus fumigatus. 
Serrawettin W1, first described as serratamolide [47], is reported to be an antimicrobial, 
antitumor and plant-protecting molecule, making this biosurfactant an interesting candidate for 
cosmetics or pharmaceuticals applications [48–50]. Very recently, Kadouri and Shanks [51] 
demonstrated the inhibitory activity of this compound against MRSA strains and other Gram-positive 
organisms. Furthermore, despite the cytotoxic activity of serratamolide, the authors suggest that 
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bacterial aminolipids may be a source for future antibiotics effective against MRSA and may play a 
role in microbial competition. 
Samadi et al. [52] evaluated some biological activities of mono and di-rhamnolipids produced 
by P. aeruginosa MN1 and reported that the mono-rhamnolipid fraction was a more potent 
antibacterial agent than the di-rhamnolipid fraction, in particular, against Gram-positive bacteria that 
were inhibited at 25 μg ml−1 concentration. Moreover, the rhamnolipids remarkably enhanced 
oxacillin inhibitory effects against MRSA strains lowering its minimum inhibitory concentrations to 
3.12–6.25 μg ml−1.  
Rhamnolipids were also examined to evaluate their antimicrobial potential against alone and 
when combined with nisin (a food preservative) against two wild-type strains of L.   
monocytogenes [53]. Rhamnolipids alone had an MIC values ranging from 78 to 2500 mg ml−1, 
which was significantly reduced when in combination of nisin showing strong synergistic effect 
against L. monocytogenes isolates.  
In other works Luna et al. [54] and Rufino et al. [55] demonstrated antimicrobial activity of two 
biosurfactants derived respectively from Candida sphaerica UCP0995 and Candida lipolytica UCP 
0988, known to produce sophorolipids (SL), against Gram-positive strains such as Streptococcus 
mutans, Streptococcus sanguis, Streptococcus agalactiae, S. epidermidis, Streptococcus oralis, and 
against C. albicans. Synergistic effects for sophorolipids biosurfactants (SL) with selected antibiotics 
were also reported by Joshi-Navare and Prabhune [56]. A strain of S. aureus was not  totally 
inhibited by tetracycline at the concentration of 15 µg ml-1 after 6h exposure but was totally inhibited 
within 4h when combined with sophorolipids (at 300 µg ml−1). Similarly, Cefaclor antibiotic showed 
better effects on E. coli when administered in combination with SL. Scanning electron microscopy 
revealed that the cells treated with mixtures of SL and antibiotics were characterized by cell 
membrane damage and pore formation, leading to enhanced leakage of the cytoplasmic contents and 
accumulation of cell debris. Similarly, a glycolipid biosurfactant from Halomonas sp BS4, containing 
1, 2-Ethanediamine N, N, N’, N’- tetra and (Z)-9-octadecenamide, showed antibacterial activity 
against S. aureus, K. pneumoniae, Streptococcus pyrogenes and Salmonella typhi and antifungal 
activity against Aspergillus niger, Fusarium sp, Aspergillus flavus and Trichophyton rubrum [57]. 
In spite of the high number of publication describing the antimicrobial activity of biosurfactants 
and of patents related to their usage, real applications in pharmaceutical, biomedical and health 
improvement related industries remains quite limited [4]. Some lipopeptides have reached a 
commercial antibiotic status, like echinocandins [58], micafungin [59], anidulafungin [60] and 
daptomycin [61]. Daptomycin a branched cyclic lipopeptide isolated from cultures of S. roseosporus 
and produced by Cubist Pharmaceuticals under the name Cubicin® [61], was approved in 2003 for 
skin infections treatment caused by MRSA and other Gram-positive pathogens and in 2006 for the 
treating endocarditis and bacteraemia usually caused by S. aureus. Daptomycin had also been 
reported to displays strong antibacterial activity against other important pathogens, such as 
penicillin-resistant Streptococcus pneumoniae, coagulase-negative Staphylococci (CNS), 
glycopeptide-intermediate-susceptible S. aureus (GISA) and vancomycin resistant Enterococci  
(VRE) [62].  
Other lipopeptides such as micafungin, echinocandins and anidulafungin are low-toxic 
synthetically modified lipopeptides, usually obtained from the fermentation broths of various   
fungi [63]. Echinocandins can inhibit fungal cell wall formation particularly against Aspergillus spp. 
Candida spp. and Pneumocystis carinii [64]. The first licensed echinocandin was caspofungin; 
approved since 2001 for the treatment of invasive aspergillosis, esophageal and invasive candidiasis 
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particularly in difficult to treat cases [58]. Micafungin has been used to combat Candida and 
Aspergillus invasive infections in immune compromised children [59] whereas anidulafungin in the 
treatment of all forms of candidiasis [60]. Other lipopeptides suitable for the prevention or treatment 
of microbial infections have also been described as suitable antimicrobial agents with pharmaceutical 
applications [65]. For example, viscosin lipopeptides and congeners have been patented as 
therapeutic compounds capable of inhibiting Trypanosoma cruzi, Mycobacterium tuberculosis and a 
Herpes simplex virus [66]. 
2.2.2. Antiviral activity of biosurfactants 
Antiviral activity of biosurfactants has also been observed, mostly against enveloped viruses, 
such as herpes viruses and retroviruses compared to non-enveloped viruses. This is believed to be 
due to the inhibitory action and physico-chemical interactions between the surfactants and the virus 
envelope [67]. Antiviral activity against bursal disease virus and newcastle disease virus was 
observed for lipopeptides produced by B. subtilis fmbj [68]. Similarly, sophorolipids and 
rhamnolipids alginate complex showed antiviral activity against HIV, human immunodeficiency 
virus [69] and herpes simplex viruses [70] respectively. 
2.3. Biosurfactants role in biofilms and as anti-adhesives 
The continuous increase in the use of medical devices is often associated with tangible risk of 
infectious complications, endocarditis, metastatic infections, septic thrombophlebitis and sepsis. 
These microbial infections are usually due to the formation of biofilms, complex biological 
structures adhering to the medical device consisting of a sessile and multicellular community 
encapsulated in a hydrated matrix of proteins and polysaccharides. Once a mature biofilm is 
established, the bacterial strains embedded within become greatly resistant to both antimicrobial 
agents [71] and host immune response. The Gram-positive bacteria S. aureus, S. epidermidis, E. 
faecalis, constitute >50% of the species isolated from patients with infections related to medical 
device biofilms such as catheter associated infections. P. aeruginosa, Candida spp. and 
uropathogenic E. coli are the remaining causal agents. Similarly, orthopedic metallic prostheses are 
associated with a significant risk of infection [72,73].  
Coating medical surfaces with antimicrobial agents are the most common current biofilm 
preventive strategies, a process not always successful [74]. Surface modification strategies based on 
plasma, UV and corona discharge treatment of typical catheter materials, such as silicone and 
polyurethanes, have been developed with the aim to increase material hydrophilicity, thus decreasing 
microbial adhesion and biofilm formation [75]. Such modifications have a temporary effect on 
silicone, due to the rapid rearrangement of macromolecular chains, leading to surface hydrophobicity 
recovery [76]. Surface coatings releasing biocides (e.g. nitric oxide, antibiotics or silver) have been 
developed on metallic and polymer biomaterials, as short term antimicrobial strategies [77]. The 
main drawbacks of antimicrobial coatings arise from time limited effectiveness as in the case of 
PEG-based coatings, which are susceptible to oxidative degradation [78], development of 
microorganism resistance and potential toxicity towards human cells as in the case of quaternary 
ammonium salts coatings [79]. 
In this context, biosurfactants have recently emerged as a potential new generation of 
anti-adhesive agents with enhanced biocompatibility. Biosurfactants have demonstrated the ability to 
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disrupt biofilm formation, controlling microbial interaction with interfaces by altering the chemical 
and physical condition of the developing biofilms environments [30,80]. 
2.3.1. Anti-adhesives/biofilm lipopeptides biosurfactants 
Rivardo et al. [81], reported that a lipopeptide biosurfactant produced by the strain B. subtilis 
V9T14 in association with antibiotics synergistically increased the efficacy of antibiotics against 
biofilm formation of the pathogenic E. coli CFT073. Some of the combinations used led to the 
complete eradication of its biofilm. This has been used to obtain an international patent on this 
application [82]. Combinations of the biosurfactant with biocides to act as adjuvants were designed 
to effectively prevent biofilms formation on biotic and abiotic surfaces and/or eradicating planktonic 
bacterial growth. 
Janek et al. [83] investigated the role and applications of pseudofactin II, cyclic lipopeptide 
biosurfactant produced by Pseudomonas fluorescens BD5, as an anti-adhesive compound for 
therapeutic and medicinal applications. Pseudofactin II decreased the adhesion of Enterococcus hirae, 
Proteus mirabilis, S. epidermidis, E. faecalis, E. coli, and C. albicans to glass, polystyrene and 
silicone. In particular, pre-treatment of a polystyrene surface with pseudofactin II (0.5 mg ml−1) 
reduced C. albicans adhesion by 92–99% and other bacterial adhesion by 36–90%. It also led to 
increased biofilm removal ability on pre-existing biofilms grown on untreated surfaces. Pseudofactin 
II also caused a significant inhibition of the initial adhesion of E. coli, E. hirae, E. faecalis and C. 
albicans strains onto silicone urethral catheters. At the highest concentration tested (0.5 mg ml−1) 
total inhibition of growth was observed for S. epidermidis while partial growth inhibitions occurred 
on other bacteria and C. albicans yeast.   
In other work, Paenibacillus polymyxa lipopeptide biosurfactants were able to inhibit mixed and 
single species biofilms [84]. This biosurfactant complex mainly composed of fusaricidin B and 
polymyxin D1, reduced the biofilm biomass for P. aeruginosa, S. aureus, B. subtilis, Micrococcus 
luteus, and Streptococcus bovis. Sriram et al. [85] also reported antimicrobial activity and biofilm 
inhibition using a lipopeptide biosurfactant produced by a soil strain of Bacillus cereus resistant to 
the heavy metals lead, iron and zinc. It also inhibited biofilm formation in pathogenic strains of S. 
aureus and P. aeruginosa. Maximum biofilm inhibition (57%) was observed against S. epidermidis at 
15 mg ml−1.  
Zeraik and Nitschke [86] evaluated the anti-adhesive and attachment properties for M. luteus, L. 
monocytogenes and S. aureus on polystyrene surfaces at various temperatures upon treatment with 
rhamnolipids and surfactin. Rhamnolipids showed a slight decrease in the attachment of S. aureus 
but were generally not effective. Surfactin in comparison effectively inhibited adhesion of tested 
bacterial strains at all conditions with increased activity as temperature decreased with maximum 
63–66% reduction in adhesion at 4 °C.  
Prevention of C. albicans biofilm formation on silicone disks and on acrylic resins for denture 
prostheses by lipopeptide biosurfactants produced by Bacillus sp. were reported by Cochis et al. [12]. 
Pre-coating with biosurfactants resulted in greater biofilm reduction and drop in cell number viability 
than did chlorhexidine disinfectant. This anti-adhesion activity was detected at fairly low 
concentrations (78–156 μg ml−1) which were non-cytotoxic. In another work, the lipopeptide 
biosurfactant produced by Bacillus tequilensis CH (CHBS) was able to inhibit biofilm formation of 
pathogenic bacteria on both hydrophilic and hydrophobic surfaces [87]. E. coli and S. mutans 
biofilms were grown with different concentrations of biosurfactant on glass pieces or polyvinyl 
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chloride surfaces. Biofilms of E. coli and S. mutans were observed on the surfaces co-incubated with 
0 and 25 μg ml−1 CHBS, whereas there was a complete absence of biofilm on the surfaces incubated 
with 50 and 75 μg ml−1 CHBS. Interestingly, CHBS did not inhibit the growth of E. coli and S. 
mutans planktonic cells under all tested concentrations, demonstrating that CHBS was not a 
bactericidal agent but only contrasted bacterial adhesion to different surfaces [87]. 
Recent research at the author’s laboratory reported on a biosurfactant produced by Lactobacillus 
brevis CV8LAC, which significantly reduced biofilm formation and adhesion of C. albicans on 
silicone elastomeric disks [88]. In particular, co-incubation with CV8LAC biosurfactant significantly 
reduced biofilm formation by about 90%, whereas pre-coating of silicone disks reduced fungal 
adhesion of about 60%. The growth of C. albicans in both sessile and planktonic form was not 
inhibited; suggesting that biosurfactant CV8LAC remarkably affected cell-surface interactions 
making the surface less supportive for microbial adhesion.  
Recent unpublished results from our laboratory also showed a significant reduction of biofilm 
formation by bacterial pathogens on polystyrene coated with a lipopeptide biosurfactant obtained 
from an endophytic strain, genotypically identified as Bacillus subtilis (Figure 1A). In particular, 
biofilms of three P. aeruginosa strains were reduced in a range of about 70–90%, whereas biofilms 
of E. coli and S. epidermidis strains were inhibited of about 70%.  
The same lipopeptide also showed the ability to significantly reduce biofilm formation for C. 
albicans on biosurfactant-coated silicone elastomeric disks (Figure 1B). Chemical analysis of the 
crude extract revealed the presence of two families of lipopeptides, principally surfactin and a lower 
percentage of fengycin. 
2.3.2. Anti-adhesives/biofilm glycolipid biosurfactants 
Rhamnolipids and other surface-active plant oil extracts have recently been observed by some 
of the author’s laboratories to have a significant role in the inhibition of complex biofilms and to act 
as adjuvants enhancing selected antibiotics microbial inhibitors [15]. In another study, a glycolipid 
biosurfactant from P. aeruginosa DSVP20 was evaluated for its ability to disrupt C. albicans biofilm. 
The treatment with the di-rhamnolipid (RL-2) at concentrations ranging from 0.04–5.0 mg ml−1 
significantly reduced C. albicans adhesion on polystyrene surfaces (PS) in a dose-dependent manner. 
Data showed a reduction of the number of adherent cells, after 2h of treatment, of about 50% with 
0.16 mg ml−1 RL-2, that gradually increased up to a complete inhibition of adherence at a 
concentration of 5 mg ml−1. Moreover, C. albicans biofilm on PS surface was disrupted up to 70% 
and 90% with RL-2 treatment at concentrations of 2.5 and 5.0 mg ml−1, respectively [89]. Also 
recently, Pradhan et al. [90] reported a new glycolipid obtained from Lysinibacillus fusiformis S9 
with remarkable anti-biofilm activity against pathogenic E. coli and S. mutans, while not affecting 
microbial cell viability. In particular, the biosurfactant was able to completely contain the biofilms 
formation at a concentration of 40 μg ml−1. 
Recent unpublished data obtained at the author’s laboratory investigating anti-biofilm activities 
of rhamnolipid biosurfactants against Gram-negative and Gram-positive pathogens on polystyrene 
are presented in Figure 2. The rhamnolipid extract, obtained from a P. aeruginosa isolated from 
cystic fibrosis patient (strain 89), was utilized at a concentration of 500 μg ml−1. 
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Figure 1. Anti-adhesion activity of a lipopeptide biosurfactant (LpBS) against 
bacterial and fungal biofilm. (A) Bacterial biofilm reduction on polystyrene coated 
by a LpBS after 24 hours incubation. The assay was carried out in Calgary Biofilm 
Device [MBEC Minimum Biofilm Eradication Concentration] AssayTM, 
Innovotech, St. Edmonton, Canada] by means of MTT method. The asterisks [*] 
indicate the level of statistical significance as determined by Student’s t-test [*** p < 
0.001]; (B) C. albicans biofilm reduction on silicone disks coated with a lipopeptide 
biosurfactant at 24, 48 and 72 hours of incubation. 
It was observed that rhamnolipid significantly reduced biofilm formation abilities of the 
Gram-positive S. epidermidis and the Gram-negative E. coli respectively of 75% and 82%. The 
observed reductions of three related P. aeruginosa strains were at average of 31%. It is known that 
rhamnolipids play an important role at different stages of P. aeruginosa biofilm development and that 
their effect is concentration-dependent. While low amounts of rhamnolipids increase initial 
adherence of cells to a surface and microcolonies formation, the presence of high concentrations in 
the medium (as in the case of the anti-adhesion assay), limits attachment of the cells and further 
microcolonies formation [91], most likely leading to a reduction of biofilm.  
Additional chemical analyses are underway to identify the type rhamnolipids produced by P. 
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aeruginosa 89 strain, however it most likely will be a mixture of the mono and di rhamnolipids with 
the 10 carbon fatty acids side chains typical of P. aeruginosa strain. The encouraging results obtained 
against biofilm producer strains make this biosurfactant a good candidate to prevent adhesion on 
plastic surfaces. 
Padmapriya and Suganthi [92] have partially purified two biosurfactant produced by C. 
tropicalis and C. albicans and tested their anti-adhesive activity on different types of urinary and 
clinical pathogens. The results showed a reduction of adherent cells on the surface of urinary catheter 
pre-coated with biosurfactants and a higher activity of the biosurfactant synthesized by C. tropicalis 
in comparison with the biosurfactant synthesized by C. albicans. 
 
Figure 2. Bacterial biofilm reduction on polystyrene coated by a rhamnolipid 
biosurfactant (RhBS) after 24 hours incubation. The assay was carried out in 
Calgary Biofilm Device [MBEC Minimum Biofilm Eradication Concentration] 
AssayTM, Innovotech, St. Edmonton, Canada] by means of MTT method. The 
asterisks [*] indicate the level of statistical significance as determined by Student’s 
t-test [* p < 0.05; ** p < 0.01]. 
The effect of the Lactobacillus acidophilus DSM 20079 biosurfactant on adherence and on the 
expression level of the genes gtf B and gtf C in S. mutans biofilm cells was also analyzed by 
Tahmourespour et al. [93]. The L. acidophilus biosurfactant was able to interfere with the adhesion 
and biofilm formation of S. mutans to glass slide and led to shorter chains formation. Moreover, 
several properties of S. mutans cells (adhesion ability, biofilm formation, surface properties and gene 
expression) were altered as a result of treatment with L. acidophilus biosurfactant. A patent has been 
granted for Lactobacillus biosurfactants ability to inhibit bacterial pathogens attachment and 
colonization on medical devices particularly to prevent urogenital infection in mammals [94]. The 
anti-adhesive activity of a lipopeptide biosurfactant secreted by the probiotic strain 
Propionibacterium freudenreichii was analysed by Hajfarajollah et al. [95]. It showed a significant 
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anti-adhesive action against a wide range of pathogenic bacteria and fungi (S. aureus, B. cereus, P. 
aeruginosa, E. coli). The highest adhesion reduction was obtained for P. aeruginosa (67.1%) at the 
concentration of 40 mg ml-1, whereas lower activities were observed for S. aureus (32.3%), B. cereus 
(39.1 %) and E. coli (47.7%), at the same concentration. 
2.4. Therapeutic and biotechnological applications 
Mannosylerythritol lipids (MELs), surfactin and trehalose lipids, all often reported as very 
powerful biosurfactant molecules, are known to have immunosuppressive and immunomodulating, 
anti-tumour and anti-inflammatory activity in addition to other properties such as cells stimulation 
and differentiation, cell-to-cell signalling, self-assembling, interaction with stratum corneum lipids, 
membrane perturbation and haemolytic activity [6]. Antitumor activities were described for surfactin 
by Cao et al. [96] and for other lipopeptides by Saini et al. [35]. Significant effects against tumour 
cell lines were also observed for serratamolide AT514, a cyclic depsipeptide from Serratia 
marcescens [97] and for glycolipids, in particular mannosylerythritol lipids (MELs) [98] and 
sophorolipid [99]. 
Surfactin also showed interesting anti-inflammatory activities due to its inhibitory properties on 
phospholipase A2, on the release of Interleukin (LK-6) and the overproduction of nitric oxide [100]. 
Park et al. [101] explored the mechanisms by which surfactin induced anti-inflammatory actions in 
relation to serious gum infection caused by Porphyromonas gingivalis. These authors also observed 
that surfactin significantly reduced the pro-inflammatory cytokines, including interleukin IL-6, IL-12 
and IL-1β and tumour necrosis factor-α, through suppression of nuclear factor κB activity in P. 
gingivalis. The role of surfactin in the inhibition of the immunostimulatory functions of macrophages 
through blocking the NK-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) and 
MAPK (mitogen-activated protein kinases) and Akt (serine/threonine kinase Akt, also known as 
protein kinase) cell signalling pathway suggests important immunosuppressive capabilities for this 
molecule [102]. 
Properties such as emulsification, foaming, detergency, and dispersion render biosurfactants 
curious molecules with several potential application in areas of drug delivery [103]. Rhamnolipids 
liposomes have been patented some time ago as drug and other molecules delivery system as 
microcapsules containing these drugs, proteins, nucleic acids and dyes and with an the ability to 
biomimetic biological membranes and acting as sensors for the detection of pH variations. Nguyen  
et al. [104] reported on using sophorolipids and rhamnolipids mixed with lecithins to prepare 
biocompatible micro-emulsions suitable for both cosmetic and drug delivery applications. Other 
biosurfactants such as fengycin and surfactin were also reported suitable as enhancers for the skin 
accumulation and transdermal penetration of antiviral drug acyclovir increasing its concentration in 
the epidermis by a factor of two [105]. 
Finally, biosurfactant mediated nanomaterial synthesis and/or stabilization has recently been 
emerging as a “green chemistry” clean, non-toxic and environmentally acceptable procedure [106]. 
Reddy et al. [107] successfully synthesized gold and silver nanoparticles by using surfactin from the 
bacterium B. subtilis while Singh et al. [108] synthesized a highly stable cadmium sulphide 
nanoparticles using surfactin from B. amyloliquefaciens KSU-109 and both sophorolipids and 
rhamnolipids were successfully used in the synthesis and stabilization of metal-bound nanoparticles. 
Palanisamy and Raichur [109] and Kumar et al. [110] synthesized spherical nickel oxide and silver 
nanoparticles using rhamnolipids as alternative surfactant through microemulsion technique and 
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reported antimicrobial activity with the silver nanoparticles. Sophorolipids were also successfully 
used to attach silver nanoparticles to polymer scaffolding and passing on antibacterial activity [111]. 
3. Conclusions 
Microbial biofilms are recalcitrant environments often providing shelter and protection to 
producing and inhabiting microbial flora. They also are mainly responsible for many persistent 
infections in clinical environments, the dissemination of airborne pathogens and the fouling of 
industrial surfaces in clinical, food and environmental settings. These problems are progressively 
challenged by the increase in resistant microbial biofilm populations and the scarcity of alternative 
eradication solutions. Biosurfactants represent a group of emerging surface-active agents which have 
inherent anti-microbial (bacterial, fungal and viral) properties and ability to act as anti-adhesive, 
disruptive and dispersant for such biofilm structures. Their uses either on their own or as adjuvants to 
other antimicrobial, chemotherapies may represent a possible way forward in tackling infections, 
biofilms formation and microbial proliferation in the future. 
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